Anavex Life Sciences

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$0
$0
$0
$0
EBITDA
-14,729
-12,519
-9,129
-9,988
EBIT
-28,932
-24,566
-19,830
-21,970
Net Income
-12,214
-10,546
-8,622
-10,146
Net Change In Cash
0
0
0
0
Free Cash Flow
-5,180
-11,656
-7,318
-5,849
Cash
138,756
139,386
143,765
151,024
Basic Shares
84,535
82,464
82,077
79,787

Annual Financials

Values in thousands 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Revenue
$0
$0
$0
$0
EBITDA
-47,498
-50,942
-41,679
-31,063
EBIT
-47,498
-47,619
-79,134
-57,777
Net Income
-47,491
-47,977
-37,908
-26,280
Net Change In Cash
0
0
0
0
Cost of Revenue
-2,949
122,858
7,063
Free Cash Flow
-27,785
-24,237
-30,383
-21,287
Cash
151,024
149,157
152,107
29,249
Basic Shares
79,787
76,909
69,802
58,194

Earnings Calls

Quarter EPS
2024-06-30
-$0.14
2024-03-31
-$0.13
2023-12-31
-$0.11
2023-09-30
-$0.12